Consonance Capital Management LP Aurinia Pharmaceuticals Inc. Transaction History

Consonance Capital Management LP

7 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2020 Nov 16, 2020	SELL	$13.19 - $16.66 $61 Million - $77 Million	-4,621,325 Closed	0 $0
Q2 2020 Aug 14, 2020	SELL	$14.12 - $18.33 $32.3 Million - $41.9 Million	-2,288,049 Reduced 33.12%	4,621,325 $75.1 Million
Q1 2020 May 15, 2020	BUY	$11.34 - $21.46 $3.22 Million - $6.09 Million	283,703 Added 4.28%	6,909,374 $100 Million
Q4 2019 Feb 14, 2020	BUY	$3.88 - $21.42 $15.8 Million - $87.1 Million	4,064,402 Added 158.69%	6,625,671 $134 Million
Q3 2019 Nov 14, 2019	SELL	$5.34 - $6.59 $8.87 Million - $10.9 Million	-1,661,289 Reduced 39.34%	2,561,269 $13.7 Million
Q1 2019 May 15, 2019	BUY	$6.06 - $7.64 $25.5 Million - $32.2 Million	4,212,558 Added 42125.58%	4,222,558 $27.4 Million
Q4 2018 Feb 14, 2019	BUY	$5.08 - $6.83 $50,800 - $68,300	10,000 New	10,000 $68,000

207

58.6M

1.14M

1.51M

Ticker AUPH
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 141,892,000
Market Cap $1.27B
Description
Aurinia Pharmaceuticals Inc., a commercial-stage biopharmaceutical company, focuses on developing and commercializing therapies to treat various diseases with unmet medical need in the United States and internationally. The company offers LUPKYNIS for the treatment of adult patients with active lupus nephritis. It has a collaboration and license...

Get notified when there are updates to the investment portfolio of Consonance Capital Management LP, based on Form 13F filings with the SEC.

Stay updated on Consonance Capital Management LP with notifications on news.